Wedbush Morgan Downgrades Discovery Laboratories (DSCO) to Sell
More News related to DSCO
- Discovery Laboratories (DSCO) Submits Propsed Protocol for Surfaxin Clinical to U.S. FDA
- Discovery Labs Submits SURFAXIN Pharmacodynamic Trial Protocol to FDA
- Discovery Labs to Present at the Lazard Capital Markets Healthcare Conference
- Wedbush Reiterates an 'Underperform' on Discovery Laboratories (DSCO); Financing Overhang Remains;
- Discovery Labs (DSCO) Posts Q3 Loss of 6c, In-Line with Street
More News related to Downgrades
- Davenport Downgrades Nokia (NOK) to Neutral
- Sidoti & Co Downgrades Innophos Holdings (IPHS) to Neutral
- Sidoti & Co Downgrades Tyler Technologies (TYL) to Neutral
- China BAK (CBAK) Shares Tumble Amid Q4 Results, Roth Capital Downgrade
- Canaccord Adams Downgrades Micromet (MITI) to Hold
Wedbush Morgan downgrades Discovery Laboratories Inc. (Nasdaq: DSCO) from Hold to Sell, after Sufaxin program discontinued and capital restraints remain an issue.
Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases.
Related Categories
DowngradesStocks Mentioned
-0.01Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
